Corvus Pharmaceuticals Announces $150M Public Offering to Fund Clinical Trials and Extend Runway

summarizeSummary

Corvus Pharmaceuticals announced a $150 million public offering of common stock and pre-funded warrants, crucial for addressing its going concern warning and funding its clinical pipeline, following positive Phase 1 trial results for soquelitinib.

check_boxKey Events · Financing and Capital Events · CRVS

• Significant Public Offering Announced

  Corvus Pharmaceuticals is offering $150 million in common stock and pre-funded warrants, with underwriters having an option to purchase an additional $22.5 million in shares.

• Addresses Going Concern Warning

  The capital raise is vital for the company, which had previously identified conditions raising substantial doubt about its ability to continue as a going concern, and is expected to extend its cash runway into Q1 2028.

• Follows Positive Clinical Trial Results

  The offering is strategically timed with the announcement of positive Phase 1 clinical trial results for soquelitinib in moderate to severe atopic dermatitis, which likely improved the terms of the capital raise.

• Funds Key Clinical Pipeline Development

  Proceeds will be used for working capital and to advance critical clinical trials, including a Phase 3 trial for T-cell lymphoma and Phase 2 trials for atopic dermatitis, hidradenitis suppurativa, and asthma.

auto_awesomeAnalysis · CRVS · Life Sciences

Corvus Pharmaceuticals announced a substantial public offering of $150 million in common stock and pre-funded warrants, with an additional $22.5 million option for underwriters. This capital raise is critical for the company, which previously disclosed substantial doubt about its ability to continue as a going concern. The proceeds are expected to extend the company's cash runway into the first quarter of 2028, enabling it to fund working capital and advance key clinical trials, including a Phase 3 trial for T-cell lymphoma and Phase 2 trials for atopic dermatitis, hidradenitis suppurativa, and asthma. The timing of this offering coincides with the announcement of positive Phase 1 clinical trial results for soquelitinib in atopic dermatitis, which likely facilitated the capital raise at a more favorable valuation than previously possible. While the offering will result in significant dilution for existing shareholders, it provides essential funding to address liquidity concerns and progress its pipeline following encouraging clinical data.